Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 21

Sort by

Sort Order Select

Meeting Abstracts

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

RICHARD M. BERGENSTAL, STEVEN EDELMAN, PRATIK CHOUDHARY, THOMAS DANNE, ERIC RENARD, JUKKA WESTERBACKA, BHASWATI MUKHERJEE, PASCALINE PICARD, VALERIE PILORGET, TADEJ BATTELINO

Diabetes 2022;71(Supplement_1):105-LB

https://doi.org/10.2337/db22-105-LB

Published: 01 June 2022

View articletitled, 105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

Meeting Abstracts

1056-P: Reported Pregnancy Outcomes with Insulin Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) : Post-Marketing Survey of Pharmacovigilance Data

JUKKA WESTERBACKA, CAROLINE BASSOLE, MARIELLE DUVERNE, ZORAN DODER, HEIKE SCHOEPPER

Diabetes 2022;71(Supplement_1):1056-P

https://doi.org/10.2337/db22-1056-P

Published: 01 June 2022

View articletitled, 1056-P: Reported Pregnancy Outcomes with Insulin Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) : Post-Marketing Survey of Pharmacovigilance Data

Meeting Abstracts

105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study

TIMOTHY S. BAILEY, JUKKA WESTERBACKA, CHARLIE NICHOLLS, JASVINDER GILL, MERWYN JONES S, LAXMI SHENOY

Diabetes 2021;70(Supplement_1):105-LB

https://doi.org/10.2337/db21-105-LB

Published: 01 June 2021

View articletitled, 105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study

Meeting Abstracts

2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

STEWART B. HARRIS, FRANK J. SNOEK, LUIGI MENEGHINI, FELIPE LAUAND, SR., JUKKA WESTERBACKA, AUDE ROBOREL DE CLIMENS, KAMLESH KHUNTI

Diabetes 2020;69(Supplement_1):2192-PUB

https://doi.org/10.2337/db20-2192-PUB

Published: 01 June 2020

View articletitled, 2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

Meeting Abstracts

1106-P: Predictive Modeling Suggests Subgroup Effects for Severe Hypoglycemia in T2DM Patients Treated with Gla-300 vs. IDeg: The LIGHTNING Study

IRENE HRAMIAK, MARTIN HALUZIK, JUKKA WESTERBACKA, ZSOLT BOSNYAK, BJORN ELIASSON, LAWRENCE BLONDE, TIMOTHY S. BAILEY

Diabetes 2019;68(Supplement_1):1106-P

https://doi.org/10.2337/db19-1106-P

Published: 01 June 2019

View articletitled, 1106-P: Predictive Modeling Suggests Subgroup Effects for Severe Hypoglycemia in T2DM Patients Treated with Gla-300 vs. IDeg: The LIGHTNING Study

Meeting Abstracts

1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes

STEWART B. HARRIS, LORI BERARD, JUKKA WESTERBACKA, ZSOLT BOSNYAK, LYDIE MELAS-MELT, FELIPE LAUAND, SR., TIMOTHY S. BAILEY, KAMLESH KHUNTI

Diabetes 2019;68(Supplement_1):1095-P

https://doi.org/10.2337/db19-1095-P

Published: 01 June 2019

View articletitled, 1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes

Meeting Abstracts

1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT

RONAN ROUSSEL, JUAN P. FRIAS, JUKKA WESTERBACKA, ZSOLT BOSNYAK, LYDIE MELAS-MELT, LORI BERARD, ALICE Y. CHENG

Diabetes 2019;68(Supplement_1):1090-P

https://doi.org/10.2337/db19-1090-P

Published: 01 June 2019

View articletitled, 1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT

Meeting Abstracts

1098-P: Treatment Satisfaction with Gla-300, IDeg-100, and Gla-100 in Insulin-Naïve T2DM: The BRIGHT and EDITION 3 Trials

LORI BERARD, FRANK J. SNOEK, STEWART B. HARRIS, JUKKA WESTERBACKA, ZSOLT BOSNYAK, LYDIE MELAS-MELT, KAMLESH KHUNTI

Diabetes 2019;68(Supplement_1):1098-P

https://doi.org/10.2337/db19-1098-P

Published: 01 June 2019

View articletitled, 1098-P: Treatment Satisfaction with Gla-300, IDeg-100, and Gla-100 in Insulin-Naïve T2DM: The BRIGHT and EDITION 3 Trials

Meeting Abstracts

133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk)

SEAN D. SULLIVAN, NICK FREEMANTLE, ARJUN A. MENON, RISHAB GUPTA, JASMANDA WU, CHARLIE NICHOLLS, JUKKA WESTERBACKA, TIMOTHY S. BAILEY

Diabetes 2019;68(Supplement_1):133-LB

https://doi.org/10.2337/db19-133-LB

Published: 01 June 2019

View articletitled, 133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk)

Meeting Abstracts

135-LB: The Forgotten Populations: Real-World Patients with T2DM Not Meeting Eligibility Criteria of the Glargine 300 U/mL EDITION and BRIGHT RCTs

DIDAC MAURICIO, JUKKA WESTERBACKA, CHARLIE NICHOLLS, JASMANDA WU, RISHAB GUPTA, ARJUN A. MENON, BJORN ELIASSON

Diabetes 2019;68(Supplement_1):135-LB

https://doi.org/10.2337/db19-135-LB

Published: 01 June 2019

View articletitled, 135-LB: The Forgotten Populations: Real-World Patients with T2DM Not Meeting Eligibility Criteria of the Glargine 300 U/mL EDITION and BRIGHT RCTs

Meeting Abstracts

131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

BERNARD CHARBONNEL, VANITA R. ARODA, JUKKA WESTERBACKA, FELIPE LAUAND, SR., EMMANUELLE BOELLE, ALICE Y. CHENG, JULIO ROSENSTOCK, GEREMIA B. BOLLI

Diabetes 2019;68(Supplement_1):131-LB

https://doi.org/10.2337/db19-131-LB

Published: 01 June 2019

View articletitled, 131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

Meeting Abstracts

Similar or Lower Severe Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100), Detemir (IDet), and Insulin Degludec (IDeg) in 112,626 People with Type 2 Diabetes Mellitus (T2DM)—Predictive Modeling Using Real-World Data—Lightning

JEREMY PETTUS, TIMOTHY S. BAILEY, FANG L. ZHOU, ZSOLT BOSNYAK, JUKKA WESTERBACKA, RACHELE BERRIA, JAVIER JIMENEZ, IRENE HRAMIAK, LUIGI MENEGHINI

Diabetes 2018;67(Supplement_1):2289-PUB

https://doi.org/10.2337/db18-2289-PUB

Published: 01 July 2018

View articletitled, Similar or Lower Severe Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100), Detemir (IDet), and Insulin Degludec (IDeg) in 112,626 People with Type 2 Diabetes Mellitus (T2DM)—Predictive Modeling Using Real-World Data—Lightning

Meeting Abstracts

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+

SEAN D. SULLIVAN, TIMOTHY S. BAILEY, RONAN ROUSSEL, FANG L. ZHOU, ZSOLT BOSNYAK, RON PREBLICK, JUKKA WESTERBACKA, RISHAB GUPTA, LAWRENCE BLONDE

Diabetes 2018;67(Supplement_1):1056-P

https://doi.org/10.2337/db18-1056-P

Published: 01 July 2018

View articletitled, Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+

Meeting Abstracts

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

SEAN D. SULLIVAN, TIMOTHY S. BAILEY, RONAN ROUSSEL, FANG L. ZHOU, ZSOLT BOSNYAK, RON PREBLICK, JUKKA WESTERBACKA, RISHAB GUPTA, LAWRENCE BLONDE

Diabetes 2018;67(Supplement_1):1057-P

https://doi.org/10.2337/db18-1057-P

Published: 01 July 2018

View articletitled, Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

Meeting Abstracts

Achievement of Individualized HbA1c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study

LORI BERARD, DIDAC MAURICIO, KAMLESH KHUNTI, DENISE R. FRANCO, JUKKA WESTERBACKA, CHRISTOPHE CANDELAS, VALERIE PILORGET, RICCARDO PERFETTI, LUIGI MENEGHINI

Diabetes 2018;67(Supplement_1):1039-P

https://doi.org/10.2337/db18-1039-P

Published: 01 July 2018

View articletitled, Achievement of Individualized HbA1c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study

Meeting Abstracts

Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study

DIDAC MAURICIO, LUIGI MENEGHINI, EMANUELA ORSI, VADIM KLIMONTOV, JUKKA WESTERBACKA, LYDIE MELAS-MELT, VALERIE PILORGET, RICCARDO PERFETTI, KAMLESH KHUNTI

Diabetes 2018;67(Supplement_1):1037-P

https://doi.org/10.2337/db18-1037-P

Published: 01 July 2018

View articletitled, Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study

Meeting Abstracts

Comparable Rates of Severe Hypoglycemia in People with Type 2 Diabetes (T2DM) at High Risk of Hypoglycemia Switching to either Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—The Lightning Real-World Predictive Modeling Study

LUIGI MENEGHINI, RONAN ROUSSEL, FANG L. ZHOU, ZSOLT BOSNYAK, JUKKA WESTERBACKA, RACHELE BERRIA, JAVIER JIMENEZ, BJORN ELIASSON, IRENE HRAMIAK, TIMOTHY S. BAILEY

Diabetes 2018;67(Supplement_1):97-LB

https://doi.org/10.2337/db18-97-LB

Published: 01 July 2018

View articletitled, Comparable Rates of Severe Hypoglycemia in People with Type 2 Diabetes (T2DM) at High Risk of Hypoglycemia Switching to either Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—The Lightning Real-World Predictive Modeling Study

Journal Articles

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

Anna Kotronen, Tuulikki Seppänen-Laakso, Jukka Westerbacka, Tuula Kiviluoto, Johanna Arola, Anna-Liisa Ruskeepää, Matej Orešič, Hannele Yki-Järvinen

Diabetes 2009;58(1):203–208

https://doi.org/10.2337/db08-1074

Published: 01 January 2009

View articletitled, Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

Journal Articles

Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects

Jukka Westerbacka, Maria Kolak, Tuula Kiviluoto, Perttu Arkkila, Jukka Sirén, Anders Hamsten, Rachel M. Fisher, Hannele Yki-Järvinen

Diabetes 2007;56(11):2759–2765

https://doi.org/10.2337/db07-0156

Published: 01 November 2007

View articletitled, Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects

Journal Articles

Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity

Maria Kolak, Jukka Westerbacka, Vidya R. Velagapudi, Dick Wågsäter, Laxman Yetukuri, Janne Makkonen, Aila Rissanen, Anna-Maija Häkkinen, Monica Lindell, Robert Bergholm, Anders Hamsten, Per Eriksson, Rachel M. Fisher, Matej Orešic̆, Hannele Yki-Järvinen

Diabetes 2007;56(8):1960–1968

https://doi.org/10.2337/db07-0111

Published: 01 August 2007

View articletitled, Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity

Includes: Supplementary data

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

105-LB: Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D—The InRange Randomized Controlled Trial

1056-P: Reported Pregnancy Outcomes with Insulin Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) : Post-Marketing Survey of Pharmacovigilance Data

105-LB: Real-World Outcomes of Addition of Insulin Glargine 300 U/mL (Gla-300) to GLP-1RA Therapy in People with Type 2 Diabetes (PWD2): The DELIVER-G Study

2192-PUB: Treatment Satisfaction in People with Type 2 Diabetes (T2D) Receiving Basal Insulin (BI): Results from Real-World Studies and Randomized Controlled Trials (RCTs) with Insulin Glargine 300 U/mL (Gla-300)

1106-P: Predictive Modeling Suggests Subgroup Effects for Severe Hypoglycemia in T2DM Patients Treated with Gla-300 vs. IDeg: The LIGHTNING Study

1095-P: Early Hypoglycemia after Initiation of Second-Generation Basal Insulin (BI) Analogs: Patient Characteristics and Clinical Outcomes

1090-P: Reaching ADA Glycemic Targets without Hypoglycemia during Titration with Gla-300 and IDeg in T2DM: Exploratory Analyses from BRIGHT

1098-P: Treatment Satisfaction with Gla-300, IDeg-100, and Gla-100 in Insulin-Naïve T2DM: The BRIGHT and EDITION 3 Trials

133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk)

135-LB: The Forgotten Populations: Real-World Patients with T2DM Not Meeting Eligibility Criteria of the Glargine 300 U/mL EDITION and BRIGHT RCTs

131-LB: Differences in HbA1c Reduction between Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Adults ≥70 Years of Age with T2DM in the BRIGHT Trial

Similar or Lower Severe Hypoglycemia Rates with Insulin Glargine 300 U/mL (Gla-300) vs. Glargine 100 U/mL (Gla-100), Detemir (IDet), and Insulin Degludec (IDeg) in 112,626 People with Type 2 Diabetes Mellitus (T2DM)—Predictive Modeling Using Real-World Data—Lightning

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+

Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—DELIVER D+ Subgroup Analyses

Achievement of Individualized HbA1c Targets with Self- vs. Physician-Led Titration of Basal Insulin (BI) in People with Type 2 Diabetes (T2DM), Newly or Recently Initiated on BI—Results from the DUNE Real-World Study

Change in Insulin Dose and HbA1c by Geographical Region—Results from the Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) Study

Comparable Rates of Severe Hypoglycemia in People with Type 2 Diabetes (T2DM) at High Risk of Hypoglycemia Switching to either Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)—The Lightning Real-World Predictive Modeling Study

Hepatic Stearoyl-CoA Desaturase (SCD)-1 Activity and Diacylglycerol but Not Ceramide Concentrations Are Increased in the Nonalcoholic Human Fatty Liver

Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects

Adipose Tissue Inflammation and Increased Ceramide Content Characterize Subjects With High Liver Fat Content Independent of Obesity

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only